Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexrazoxane in Congenital Heart Surgery
NCT04997291Phase 1Unknown
- Sponsor
- University of Texas at Austin
- Start
- Apr 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dexrazoxane in congenital heart defects (CHD), sponsored by University of Texas at Austin. Primary endpoints: Peak Plasma Concentration at 24 hours, Area under the plasma concentration vs time curve at 24 hours and 2 more. Status: unknown.
02
Drugs
dexrazoxane
03
Conditions
congenital heart defects (CHD)
Beyond the preview
Go deeper on NCT04997291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04997291.